First-trimester medication abortion: anemia and blood loss.

Purpose of review: Although ample evidence demonstrates the safety and effectiveness of medication abortion, its safety in individuals with anemia is not well understood; modern literature describing quantitative blood loss from medication abortion is limited. As medication abortion is increasingly utilized, reviewing current guidelines and literature related to anemia and blood loss from medication abortion may help inform practice and future research.

Recent findings: Guidelines have not established a safe minimum level of starting hemoglobin for medication abortion or a single standard for the provision of medication abortion in the setting of anemia. Studies assessing blood loss from early medication abortion report a low mean decrease in hemoglobin (0.1-0.7 g/dl); however, these studies used a variety of medication regimens, and most exclude individuals with significant anemia (hemoglobin < 9.5-10 g/dl) and gestational duration greater than 63 days.

Summary: Communities most severely impacted by abortion restrictions and bans also experience significantly higher rates of anemia. Guidelines that restrict medication abortion to patients who meet arbitrary hemoglobin cutoffs can lead to delays and barriers to care. Studies using current medication regimens and including patients with moderate-to-severe anemia and gestational duration greater than 63 days are needed to inform eligibility and safety, and support provider buy-in and equity.